Researchers have developed DROP-CAR technology, a new type of CAR T cell therapy that can be remotely controlled using an existing cancer drug called venetoclax to switch off its activity when needed. This advancement addresses safety concerns by reducing side effects and enabling better control over the treatment, potentially expanding the applicability of CAR T therapies to more types of cancers and patients.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
Views10
Ali NematiBlogUI.author_articles
